Glycaemic control improves fibrin network characteristics in type 2 diabetes - A purified fibrinogen model

Thrombosis and Haemostasis

Volumn 99, Issue 4, 2008, Pages 691-700

  Pieters, Marlien ^a   Covic, Namukolo ^a   Van Der Westhuizen, Francois H ^a   Nagaswami, Chandrasekaran ^b   Baras, Yelena ^b   Loots, Du Toit ^a   Jerling, Johann C ^a   Elgar, Dale ^a   Edmondson, Kathryn S ^b   Van Zyl, Danie G ^c   Rheeder, Paul ^c   Weisel, John W ^b  

^a NORTH WEST UNIVERSITY   (South Africa)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Diabetes; Fibrin network; Fibrinogen glycation; Glycaemic control; Hyperglycaemia

Indexed keywords

FIBRIN; FIBRINOGEN; GLUCOSE; INSULIN ASPART; INSULIN GLARGINE; MARKER; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRIN CLOT; GLYCATION; GLYCEMIC CONTROL; HUMAN; KINETICS; LYSIS; MALE; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PERMEABILITY; PRIORITY JOURNAL;

ADULT; AGED; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CROSS-LINKING REAGENTS; DIABETES MELLITUS, TYPE 2; ELASTICITY; FACTOR XIIIA; FEMALE; FIBRIN; FIBRINOGEN; FIBRINOLYSIS; GLYCOSYLATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 43749099675     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-11-0699     Document Type: Article

References (36)

1. Rett K. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes Metab 1999; 1 (Suppl 1): S8-16.
2. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540.
3. Collet JP, Allali Y, Lesty C, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 2567-2573.
4. Collet JP, Park D, Lesty C, et al. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 2000; 20: 1354-1361.
5. Bobbink IW, Tekelenburg WL, Sixma JJ, et al. Glycated proteins modulate tissue-plasminogen activator-catalyzed plasminogen activation. Biochem Biophys Res Commun 1997; 240: 595-601.
6. Krantz S, Lober M, Thiele M, et al. Properties of in vitro nonenzymatically glycated plasma fibrinogens. Exp Clin Endocrinol 1987; 90: 37-45.
7. Ney KA, Pasqua JJ, Colley KJ, et al. In vitro preparation of nonenzymatically glucosylated human transferrin, alpha 2-macroglobulin, and fibrinogen with preservation of function. Diabetes 1985; 34: 462-470.
8. Mirshahi M, Soria J, Soria C, et al. Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). Thromb Res 1987; 48: 279-289.
9. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin. Diabetes 1983; 32: 680-684.
10. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-1206.
11. Nair CH, Azhar A, Wilson JD, et al. Studies on fibrin network structure in human plasma. Part II - Clinical application: diabetes and antidiabetic drugs. Thromb Res 1991; 64: 477-485.
12. Lutjens A, Jonkhoff-Slok TW, Sandkuijl C, et al. Polymerisation and crosslinking of fibrin monomers in diabetes mellitus. Diabetologia 1988; 31: 825-830.
13. Jorneskog G, Egberg N, Fagrell B, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
14. Pieters M, Covic N, Loots dT, et al. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. Thromb Haemost 2006; 96: 623-629.
15. Dunn EJ, Philippou H, Ariens RA, et al. Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 2006; 49: 1071-1080.
16. Jorneskog G, Hansson LO, Wallen NH, et al. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1: 1195-1201.
17. Dunn EJ, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. Herz 2004; 29: 470-479.
18. Barazzoni R, Zanetti M, Davanzo G, et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000; 85: 3121-3125.
19. Pieters M, van Zyl DG, Rheeder P, et al. Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb Res 2007; 120: 439-446.
20. Takebe M, Soe G, Kohno I, et al. Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 1995; 73: 662-667.
21. Blomback B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
22. Fatah K, Hamsten A, Blomback B, et al. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
23. Langer BG, Weisel JW, Dinauer PA, et al. Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem 1988; 263: 15056-15063.
24. Woodhead JL, Nagaswami C, Matsuda M, et al. The ultrastructure of fibrinogen Caracas II molecules, fibers, and clots. J Biol Chem 1996; 271: 4946-4953.
25. Sakharov DV, Nagelkerke JF, Rijken DC. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy. J Biol Chem 1996; 271: 2133-2138.
26. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
27. Field AP. Discovering statistics using SPSS. 2nd ed. London: Sage Publications; 2005.
28. Ryan EA, Mockros LF, Weisel JW, et al. Structural origins of fibrin clot rheology. Biophys J 1999; 77: 2813-2826.
29. Weisel JW, Veklich Y, Gorkun O. The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots. J Mol Biol 1993; 232: 285-297.
30. Mihalyi E. Clotting of bovine fibrinogen. Kinetic analysis of the release of fibrinopeptides by thrombin and of the calcium uptake upon clotting at high fibrinogen concentrations. Biochemistry 1988; 27: 976-982.
31. Di Stasio E, Nagaswami C, Weisel JW, et al. Cl-regulates the structure of the fibrin clot. Biophys J 1998; 75: 1973-1979.
32. Veklich YI, Gorkun OV, Medved LV, et al. Carboxyl-terminal portions of the alpha chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated alpha C fragments on polymerization. J Biol Chem 1993; 268: 13577-13585.
33. Weisel JW. The mechanical properties of fibrin for basic scientists and clinicians. Biophys Chem 2004; 112: 267-276.
34. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
35. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
36. Shacter E, Williams JA, Levine RL. Oxidative modification of fibrinogen inhibits thrombin-catalyzed clot formation. Free Radic Biol Med 1995; 18: 815-821.